Dr. Jacque Sokolov, MD, Chairman & CEO, SSB Solutions, Inc, says that value-based products and the revenue flow associated with them is evolving on the commercial side as well as the Medicare and Medicaid sides. The revenue sharing programs are contrasted with fee-for-service contracts. Dr. Sokolov also says that value-based reimbursement can have more than 5 revenue streams including quality metrics, shared savings, patient care management fees, and other areas where physicians and hospitals can recieve additional revenues for performance in value-based areas.
This video was taken on November 8 at the NAMCP Fall Forum in Las Vegas, NV.
Two new studies in The American Journal of Managed Care find that state Medicaid restrictions on access to newer antipsychotic drugs save little in the short run, and may cost more later when patients fail to stay on their medication, end up in the hospital, or both.
The 2014 Spring Managed Care Forum, held April 24-25 in Orlando, FL, will feature sessions and discussions on today’s most important topics in healthcare. The Forum includes members and executives from the American Association of Integrated Healthcare Delivery Systems (AAIHDS), the American Association of Managed Care Nurses (AAMCN), and the National Association of Managed Care Physicians (NAMCP). Check back here for continuing conference coverage, or you can sign up for our daily e-mail blasts on our registration page.
Doctors should consider expensive new hepatitis C drugs for patients with advanced liver disease, including those awaiting transplants, but ask most others to wait for drugs in development, the Department of Veterans Affairs said Wednesday.
A US Department of Health and Human Services (HHS) analysis determined that a new payment formula, which would reduce Medicaid reimbursement rates for generic prescription drugs, could save Medicaid up to $1.2 billion per year. So why are pharmacists and drug manufacturers pushing back?
Pharmacists and drug manufacturers are pushing the CMS for a one-year transition period before states attempt to implement a new formula mandated under the Patient Protection and Affordable Care Act that will significantly trim Medicaid reimbursement rates for generic drugs.
Out-of-pocket expenses for diabetes treatment have gone down for many U.S. patients over the past decade, according to a new study. But nearly a quarter of people with diabetes still face high expenses.